Neurogene (NGNE) Preferred Shares Repurchased (2013 - 2014)
Neurogene (NGNE) reported Preferred Shares Repurchased of -$99.0 for Q3 2014, down 1514.29% on a YoY basis from $7.0 in Q3 2013, and up 79.84% quarter-over-quarter from -$491.0 in Q1 2014.
Neurogene (NGNE) Preferred Shares Repurchased (2013 - 2014) Analysis & Trends
Neurogene has reported Preferred Shares Repurchased for 2 years, with the latest figure at -$99.0 in Q3 2014.
- For the quarter ending Q3 2014, Preferred Shares Repurchased fell 1514.29% year-over-year to -$99.0; the trailing twelve-month figure through Dec 2014 stood at -$590.0 (down 100.0% YoY), and the FY2014 full-year result was -$590.0, down 100.0% from the prior year.
- Preferred Shares Repurchased for Q3 2014 stood at -$99.0, up from -$491.0 in the prior quarter.
- The five-year high for Preferred Shares Repurchased was $18.0 million in Q1 2013, with the low at -$491.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | -99.00 |
| Sep 30, 2014 | -99.00 |
| Mar 31, 2014 | -491.00 |
| Mar 31, 2014 | -491.00 |
| Dec 31, 2013 | 3,032.00 |
| Dec 31, 2013 | 3,032.00 |
| Sep 30, 2013 | 7.00 |
| Sep 30, 2013 | 7.00 |
| Mar 31, 2013 | 18.00 Mn |
| Mar 31, 2013 | 18.00 Mn |